LGC has sold DDS to Alliance Pharma, a portfolio company of Ampersand and KKR
LGC Drug Development Solutions
LGC’s Drug Development Solutions (DDS) Business Unit is a leading European contract research organization (CRO) that helps clients accelerate, enhance and achieve their product and drug development goals. It has one of the largest concentrations of analytical scientists and experts in Europe with over 275 scientists split between two UK state-of-the-art facilities, in Cambridge and Sandwich, Kent.
DDS’ laboratory services covers all stages of the drug development pipeline from discovery through pre-clinical and clinical development to commercial manufacture of medicines and consumer products. The company offers unrivalled breadth and depth in bioanalysis and analytical and materials science.
Lincoln International ran a tightly run auction process focused on strategic acquirers and designed to minimize disruption. In a highly competitive process, Alliance Pharma, Inc., a US based CRO emerged as a compelling partner for the business and an attractive long term owner. DDS will form an important part of the wider Alliance Pharma, Inc. business as it builds a truly global platform.
Edward Lethbridge, Managing Director and head of Lincoln’s UK Business Services Group, commented, “The CRO and broader pharmaceutical services sector is rapidly growing with DDS representing an exciting prospect as one of the world’s largest single-site bioanalytical solutions laboratories. We are pleased to have advised LGC on their divestment and look forward to watching Alliance Pharma, Inc. continue DDS’ growth in the coming years.”
James West, Director in Lincoln’s Healthcare Group, commented, “LGC’s DDS business is European based provider of Bioanalytical and Analytical and Materials Science Solutions to pharma, biopharma, consumer healthcare and consumer products clients, and it is a natural fit with Alliance Pharma, Inc. to broaden their geographic coverage. The specific bioanalysis services across the pre-clinical and clinical phases are critical for the smooth delivery of clinical trials.”
Meet our Senior Team
View More Transactions in Business Services & Healthcare
Lincoln International advised a private equity firm on selling a medical simulation and education platform
Lincoln International is pleased to announce Parallel49 Equity on the sale of MedTorque to ARCH Medical Solutions, a portfolio company of The Jordan Company
Lincoln International has advised RoundShield Partners on its sale of a minority stake to Azimut Alternative Capital Partners, a subsidiary of Azimut Group
Lincoln International has advised Nasco, a portfolio company of EagleTree Capital, on the divestment of Whirl-Pak to Filtration Group, an affiliate of Madison Industries
Lincoln International has advised Seaside Equity Partners on the sale of Andersen Commercial Plumbing to Sun Capital Partners
Lincoln International has advised Tampa Armature Works on its sale to Integrated Power Services, a portfolio company of Searchlight Capital Partners
Lincoln International has advised Housatonic on the sale of ParaRev to CorroHealth, a portfolio company of The Carlyle Group
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.